Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

3.02
-0.1800-5.63%
Post-market: 3.070.0500+1.66%19:59 EDT
Volume:2.67M
Turnover:8.19M
Market Cap:392.81M
PE:-3.02
High:3.19
Open:3.16
Low:3.02
Close:3.20
52wk High:7.73
52wk Low:2.90
Shares:130.07M
Float Shares:124.00M
Volume Ratio:0.52
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9999
EPS(LYR):-0.9999
ROE:-50.57%
ROA:-28.17%
PB:1.75
PE(LYR):-3.02

Loading ...

Altimmune Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $12

THOMSON REUTERS
·
Mar 19

Truist Initiates Altimmune at Buy With $12 Price Target

MT Newswires Live
·
Mar 19

U.S. RESEARCH ROUNDUP-Carnival, Five Below, McKesson

Reuters
·
Mar 19

Altimmune initiated with a Buy at Truist

TIPRANKS
·
Mar 19

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

GlobeNewswire
·
Mar 18

Altimmune Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 17

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

GlobeNewswire
·
Mar 12

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

GlobeNewswire
·
Mar 09

Altimmune Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Mar 07

B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating

MT Newswires Live
·
Mar 06

Altimmune Inc. Announces 2026 Annual Stockholders Meeting

Reuters
·
Mar 06

Press Release: PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

Dow Jones
·
Mar 06

Altimmune Shares Fall After Q4 Results

MT Newswires Live
·
Mar 06

BUZZ-Altimmune falls after posting quarterly revenue below estimates

Reuters
·
Mar 06

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Rhythm Pharmaceuticals (RYTM) and Cormedix (CRMD)

TIPRANKS
·
Mar 06

Altimmune Q4 EPS $(0.27) Up From $(0.33) YoY, Sales $26.000K Up From $5.000K YoY

Benzinga
·
Mar 05

Altimmune Q4 revenue beats, EPS misses estimates

Reuters
·
Mar 05

Altimmune Q4 Operating Expenses USD 28.919 Million

THOMSON REUTERS
·
Mar 05

Altimmune Q4 Basic EPS USD -0.27

THOMSON REUTERS
·
Mar 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 05